• Je něco špatně v tomto záznamu ?

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

J. Bures, D. Kohoutova, J. Skrha, B. Bunganic, O. Ngo, S. Suchanek, P. Skrha, M. Zavoral

. 2023 ; 15 (14) : . [pub] 20230719

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015697

Grantová podpora
DZVRO MO1012 Ministry of Defence
FNHK 00179906 Ministry of Health

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis, with near-identical incidence and mortality. According to the World Health Organization Globocan Database, the estimated number of new cases worldwide will rise by 70% between 2020 and 2040. There are no effective screening methods available so far, even for high-risk individuals. The prognosis of PDAC, even at its early stages, is still mostly unsatisfactory. Impaired glucose metabolism is present in about 3/4 of PDAC cases. METHODS: Available literature on pancreatic cancer and diabetes mellitus was reviewed using a PubMed database. Data from a national oncology registry (on PDAC) and information from a registry of healthcare providers (on diabetes mellitus and a number of abdominal ultrasound investigations) were obtained. RESULTS: New-onset diabetes mellitus in subjects older than 60 years should be an incentive for a prompt and detailed investigation to exclude PDAC. Type 2 diabetes mellitus, diabetes mellitus associated with chronic non-malignant diseases of the exocrine pancreas, and PDAC-associated type 3c diabetes mellitus are the most frequent types. Proper differentiation of particular types of new-onset diabetes mellitus is a starting point for a population-based program. An algorithm for subsequent steps of the workup was proposed. CONCLUSIONS: The structured, well-differentiated, and elaborately designed approach to the elderly with a new onset of diabetes mellitus could improve the current situation in diagnostics and subsequent poor outcomes of therapy of PDAC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015697
003      
CZ-PrNML
005      
20231020093444.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15143669 $2 doi
035    __
$a (PubMed)37509329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bures, Jan $u Institute of Gastrointestinal Oncology, Military University Hospital Prague, 169 02 Prague, Czech Republic $u Department of Medicine, First Faculty of Medicine, Charles University, Prague and Military University Hospital Prague, 169 02 Prague, Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
245    10
$a Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus / $c J. Bures, D. Kohoutova, J. Skrha, B. Bunganic, O. Ngo, S. Suchanek, P. Skrha, M. Zavoral
520    9_
$a BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is associated with a very poor prognosis, with near-identical incidence and mortality. According to the World Health Organization Globocan Database, the estimated number of new cases worldwide will rise by 70% between 2020 and 2040. There are no effective screening methods available so far, even for high-risk individuals. The prognosis of PDAC, even at its early stages, is still mostly unsatisfactory. Impaired glucose metabolism is present in about 3/4 of PDAC cases. METHODS: Available literature on pancreatic cancer and diabetes mellitus was reviewed using a PubMed database. Data from a national oncology registry (on PDAC) and information from a registry of healthcare providers (on diabetes mellitus and a number of abdominal ultrasound investigations) were obtained. RESULTS: New-onset diabetes mellitus in subjects older than 60 years should be an incentive for a prompt and detailed investigation to exclude PDAC. Type 2 diabetes mellitus, diabetes mellitus associated with chronic non-malignant diseases of the exocrine pancreas, and PDAC-associated type 3c diabetes mellitus are the most frequent types. Proper differentiation of particular types of new-onset diabetes mellitus is a starting point for a population-based program. An algorithm for subsequent steps of the workup was proposed. CONCLUSIONS: The structured, well-differentiated, and elaborately designed approach to the elderly with a new onset of diabetes mellitus could improve the current situation in diagnostics and subsequent poor outcomes of therapy of PDAC.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kohoutova, Darina $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 03 Hradec Kralove, Czech Republic $u The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
700    1_
$a Skrha, Jan $u Third Department of Internal Medicine-Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, 128 08 Prague, Czech Republic
700    1_
$a Bunganic, Bohus $u Department of Medicine, First Faculty of Medicine, Charles University, Prague and Military University Hospital Prague, 169 02 Prague, Czech Republic
700    1_
$a Ngo, Ondrej $u Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 602 00 Brno, Czech Republic
700    1_
$a Suchanek, Stepan $u Institute of Gastrointestinal Oncology, Military University Hospital Prague, 169 02 Prague, Czech Republic $u Department of Medicine, First Faculty of Medicine, Charles University, Prague and Military University Hospital Prague, 169 02 Prague, Czech Republic
700    1_
$a Skrha, Pavel $u Department of Medicine, Third Faculty of Medicine, Charles University, Prague and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
700    1_
$a Zavoral, Miroslav $u Institute of Gastrointestinal Oncology, Military University Hospital Prague, 169 02 Prague, Czech Republic $u Department of Medicine, First Faculty of Medicine, Charles University, Prague and Military University Hospital Prague, 169 02 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 14 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37509329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093437 $b ABA008
999    __
$a ok $b bmc $g 1997231 $s 1202059
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 14 $e 20230719 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a DZVRO MO1012 $p Ministry of Defence
GRA    __
$a FNHK 00179906 $p Ministry of Health
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace